Immunotherapeutics in Pediatric Autoimmune CNS Disease: Agents and Mechanisms

Beyond the major advances produced by careful clinical-radiological phenotyping and biomarker development in autoimmune CNS disorders, a comprehensive knowledge of the range of available immune therapies and a deeper understanding of their action should benefit therapeutic decision-making. This review discusses the agents used in neuroimmunology and their mechanisms of action. First-line treatments typically include corticosteroids, intravenous immunoglobulin, and plasmapheresis, while for severe disease second-line ‘induction′ agents such as rituximab or cyclophosphamide are used.
Source: Seminars in Pediatric Neurology - Category: Neurology Authors: Source Type: research